Arizona Republic
Amgen will pay $762 million to settle litigation that accuses the drugmaker of marketing the anemia drug Aranesp for unapproved uses. A law firm involved in the case says the Thousand Oaks, Calif., company will pay a $612 million civil settlement, $...
Pharmalot
Amgen is expected to plead guilty today to a misbranding charge in connection with off-label marketing of medications, according to a media advisory from the US Attorney in Brooklyn, New York, and a source familiar with the proceedings. In addition,...